C4 Therapeutics (CCCC) Expected to Release Earnings on Thursday

C4 Therapeutics (NASDAQ:CCCC) will likely be issuing its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect C4 Therapeutics to post earnings of ($0.23) per share and revenue of $8.20 million for the quarter. Individuals may review the information on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, August 13, 2026 at 9:30 AM ET.

C4 Therapeutics (NASDAQ:CCCC) last released its earnings results on Tuesday, May 12th. The company reported ($0.20) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.05. C4 Therapeutics had a negative net margin of 297.76% and a negative return on equity of 50.68%. The firm had revenue of $6.15 million during the quarter, compared to the consensus estimate of $4.42 million. On average, analysts expect C4 Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

C4 Therapeutics Stock Up 3.1%

Shares of CCCC stock opened at $3.61 on Wednesday. The firm has a market cap of $399.16 million, a P/E ratio of -3.03 and a beta of 2.91. The company has a 50 day moving average of $3.95 and a 200-day moving average of $3.11. C4 Therapeutics has a 12-month low of $1.69 and a 12-month high of $5.17.

Institutional Trading of C4 Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the business. Zacks Investment Management bought a new position in C4 Therapeutics in the 3rd quarter worth approximately $29,000. Virtu Financial LLC purchased a new stake in shares of C4 Therapeutics during the fourth quarter worth $39,000. Acadian Asset Management LLC purchased a new stake in shares of C4 Therapeutics during the first quarter worth $43,000. Caitong International Asset Management Co. Ltd bought a new position in shares of C4 Therapeutics in the third quarter worth $43,000. Finally, Engineers Gate Manager LP boosted its holdings in shares of C4 Therapeutics by 49.9% in the fourth quarter. Engineers Gate Manager LP now owns 24,416 shares of the company’s stock worth $47,000 after acquiring an additional 8,130 shares during the period. Institutional investors own 78.81% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of C4 Therapeutics in a report on Friday, July 17th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $7.75.

About C4 Therapeutics

C4 Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted protein degraders. Utilizing its proprietary Controlled Inducible Degradation (CiD) platform, the company seeks to eliminate disease-causing proteins by harnessing the body’s natural protein disposal machinery. This approach aims to address a wide range of oncology and immuno-oncology indications by targeting proteins that have historically been difficult to inhibit with traditional small molecules or antibodies.

The company’s pipeline includes multiple small-molecule degrader candidates advancing through preclinical and clinical stages.